WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for
the surgical treatment of atrial fibrillation and left atrial appendage
management, will release its financial results for the first quarter of
2015 on Wednesday, April 29, 2015.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Wednesday, April 29, 2015 to discuss its first quarter 2015 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (866)
515-2911 for domestic callers and (617) 399-5125 for international
callers at least 15 minutes prior to the call start time using
participant passcode 15114945.
The webcast will be available on AtriCure’s website and a telephonic
replay of the call will be available through May 6, 2015. The replay
dial-in numbers are (888) 286-8010 for domestic callers and (617)
801-6888 for international callers. The participant passcode is 62321731.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. Afib affects more than 33 million people worldwide.
Source: AtriCure, Inc.
Andy Wade, Senior Vice President and Chief
Financial Officer, 513-755-4564